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Background
 Poxviridae are a family of DNA viruses that infect a broad range of hosts
 Orthopoxvirus genus includes several species that cause disease in 
humans
–
–
–
–
–
Variola virus (causative agent of smallpox)
Vaccinia virus (principal source of smallpox vaccine)
Monkeypox virus (cause of multiple outbreaks in Africa and imported 
cases to other countries including U.S.)
Cowpox virus (endemic in europe)
Newly discovered species (Akhmeta virus, Alaskapox virus)
Occupational Exposures
 Diagnostic laboratorians directly handle specimens from persons with 
suspect orthopoxvirus infections
 Research personnel use replication-competent orthopoxviruses in 
biomedical research
 Healthcare workers in U.S.
–
–
Administer Vaccinia virus vaccine to (e.g., to military personnel)
Would treat patients with smallpox or monkeypox due to accidental or 
intentional exposures
Serious Infections Have Occurred During Laboratory and 
Research Work
Needlestick inoculation of researcher using 
Vaccinia Virus as a vector
Ocular vaccinia in 
laboratory worker
• Vaccination with an Orthopoxvirus vaccine can prevent these infections
Vaccinia Virus Vaccine Prevents Other Orthopoxvirus
Infections
 Provides cross-protective immunity against other orthopoxviruses
 Facilitated smallpox eradication as main component of smallpox vaccine
 Recommended by ACIP for use in laboratory and healthcare personnel at 
risk for occupational exposure to orthopoxviruses
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First generation / Dryvax®
(Wyeth Laboratories, Inc.)
Propagated in calf skin
Timeline of Vaccinia Virus Vaccines Licensed at Time 
of ACIP Recommendations
2001                                            2015                                         2019
Second generation vaccine / ACAM2000™
(Acambis, Inc.™) had replaced Dryvax®
Propagated in tissue culture
Year ACIP was updated
Timeline of Vaccinia Virus Vaccines Licensed at Time 
of ACIP Recommendations
2001                                            2015                                         2019
Second generation vaccine / ACAM2000™
(Acambis, Inc.™) had replaced Dryvax®
Propagated in tissue culture
ACAM2000™
• Purified clone of strain 
used to make Dryvax®
• Safety Profile similar to 
that of Dryvax®
Timeline of Vaccinia Virus Vaccines Licensed at Time 
of ACIP Recommendations
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ACAM2000™ AND
Third generation / JYNNEOS™ 
(Bavarian Nordic) licensed
Timeline of Vaccinia Virus Vaccines Licensed at Time 
of ACIP Recommendations
2001                                            2015 2019
ACAM2000™ AND
JYNNEOS™ (Bavarian Nordic) 
licensed
JYNNEOS™ 
• Attenuated, live, replication 
deficient vaccinia virus
• Licensed in September 2019 
• Can be used in persons for 
whom ACAM2000™ is 
contraindicated
Reason for Work Group
Update ACIP recommendations for use of JYNNEOS™ to prevent 
orthopoxviruses in persons at risk for occupational exposure
Work Group Activities
 Review available data about safety and effectiveness of JYNNEOS™, 
including among persons with atopic dermatitis, immunocompromising 
conditions, and pregnancy.
 Consolidate U.S. recommendations for vaccination of persons who may 
have occupational exposures to orthopoxviruses.
 Identify areas in need of further research for informing potential future 
vaccine recommendations to prevent Orthopoxvirus infection
Step I Step II Step IV Step V
Determine scope, 
collect available 
data
Identify WG 
members
Begin Work 
Group meetings
Publish 
Guideline Recs 
based on votes
October 2019 ~January 2020 ~June 2020 2021?
Begin detailed 
presentations to 
ACIP
Step III
Nov-Dec 2019
Tentative Timeline (Subject to Change)
ACIP Work Group Co-Leads
Medical Officers, CDC Poxvirus and Rabies Branch
–
–
Agam Rao, MD 
Brett Petersen, MD MPH
ACIP Work Group Co-Leads
Medical Officers, CDC Poxvirus and Rabies Branch
–
–
Agam Rao, MD 
Brett Petersen, MD MPH
Next Steps:
 Identify work group members
 Begin review of data and work 
group meetings
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
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